Abstract: Metastatic melanoma is a recalcitrant tumor. Although "targeted" and immune therapies have been highly touted, only relatively few patients have had durable responses. To overcome this problem, our laboratory has established the melanoma patient-derived orthotopic xenograft (PDOX) model with the use of surgical orthotopic implantation (SOI). Promising results have been obtained with regard to identifying effective approved agents and experimental therapeutics, as well as combinations of the two using the melanoma PDOX model.
Introduction
Metastatic melanoma has a survival rate of 7-29%, depending on the site of metastasis [1] . Recent use of targeted chemotherapy and immunotherapy has not significantly increased the survival rate [2] . The standard first-line therapy has been decarbazine and cisplatinum (CDDP), with limited efficacy [3] [4] [5] . Vemurafenib (VEM) has had some success as a targeted therapy of melanoma that has the BRAF-V600E mutation [3, [6] [7] [8] [9] .
PD-1/PD-L1 immunotherapy has shown promise with melanoma, but is limited by tumor infiltration of activated T cells [5] , and has not increased the survival rate [2] .
Stage III and IV melanoma is almost never curable, due to a lack of effective drugs, resistance to immunotherapy and tumor heterogeneity [10] . Chemotherapy and radiotherapy of melanoma are also limited by melanin [11] . Individualized and precision therapy is needed for melanoma.
To achieve this goal, the patient-derived orthotopic xenograft (PDOX) nude mouse model using surgical orthotopic implantation (SOI) [12] has been developed in our laboratory. PDOX models of pancreatic [13] [14] [15] [16] , breast [17] , ovarian [18] , lung [19] , cervical [20] , colon [21] [22] [23] , stomach [24] and sarcoma cancers [25] [26] [27] [28] [29] have been developed. Fluorescence-guided surgery [14, 23, 30] and tumor-targeting bacteria [15, [27] [28] [29] 31] have been developed with the PDOX models. The tumor microenvironment has also been studied in the PDOX models [32, 33] . The PDOX models have been shown to have advantages over subcutaneous-transplant models, particularly with metastasis [12] .
The present report reviews our laboratory's experience with PDOX models of melanoma, and the ability of the PDOX models to identify effective currently-used-as well as experimental-therapeutics.
Tumor-targeting Salmonella typhimurium A1-R (S. typhimurium A1-R) contains auxotrophic mutations for leucine (leu) and arginine (arg), and therefore does not continuously infect normal tissue [34, 35] . S. typhimurium A1-R has shown significant efficacy against mouse models of various cancer cell lines including prostate [36, 37] , breast [38] [39] [40] , lung [41, 42] , pancreatic [15, 31, [43] [44] [45] , ovarian [46, 47] stomach [48] , and cervical cancers [49] , as well as sarcoma cell lines [50] [51] [52] , glioma [53, 54] , and the PDOX models mentioned above [15, [27] [28] [29] 31] . 
S. typhimurium A1-R Was Highly Effective on the Patient-Derived Orthotopic Xenograft (PDOX) Melanoma in Nude Mice
S. typhimurium A1-R, expressing green fluorescent protein (GFP), extensively targeted the tumor, with very few GFP-expressing bacteria found in other organs (i.e., demonstrating high tumor selectivity). S. typhimurium A1-R strongly inhibited the growth of the melanoma (Figure 1 ). S. typhimurium A1-R, cisplatinum (CDDP), and a combination of S. typhimurium A1-R and CDDP, were all highly effective on the melanoma PDOX (Figure 2) 
S. typhimurium A1-R, expressing green fluorescent protein (GFP), extensively targeted the tumor, with very few GFP-expressing bacteria found in other organs (i.e., demonstrating high tumor selectivity). S. typhimurium A1-R strongly inhibited the growth of the melanoma (Figure 1 ). S. typhimurium A1-R, cisplatinum (CDDP), and a combination of S. typhimurium A1-R and CDDP, were all highly effective on the melanoma PDOX (Figure 2 ) [34] . [34] . ** p < 0.01, compared with the untreated control group.
PDOX Model of a BRAF-V600E Mutant Melanoma
A BRAF-V600E mutant melanoma PDOX was established. VEM, temozolomide (TEM), trametinib (TRA) and cobimetinib (COB) were all effective against it. TRA treatment caused tumor regression ( Figure 3 ). The PDOX was expected to be sensitive to VEM, since VEM targets the BRAF-V600E mutation. However, in this case, TRA was much more effective than VEM [55] . This result shows that the BRAF-V600E mutation is probably not a major factor in promoting this melanoma, and that genomic profiling by itself is insufficient to direct therapy. Only trametinib (TRA) could regress the tumor. Vemurafenib (VEM) was not very effective despite the fact that it targets the BRAF-V600E mutation in this tumor. ** p ≤ 0.0001. Error bars = SD [55] .
In a subsequent study with this BRAF-V600E mutant melanoma PDOX, TEM combined with S. typhimurium A1-R was significantly more effective than either S. typhimurium A1-R and TEM alone, [34] . ** p < 0.01, compared with the untreated control group.
A BRAF-V600E mutant melanoma PDOX was established. VEM, temozolomide (TEM), trametinib (TRA) and cobimetinib (COB) were all effective against it. TRA treatment caused tumor regression ( Figure 3 ). The PDOX was expected to be sensitive to VEM, since VEM targets the BRAF-V600E mutation. However, in this case, TRA was much more effective than VEM [55] . This result shows that the BRAF-V600E mutation is probably not a major factor in promoting this melanoma, and that genomic profiling by itself is insufficient to direct therapy. 
In a subsequent study with this BRAF-V600E mutant melanoma PDOX, TEM combined with S. typhimurium A1-R was significantly more effective than either S. typhimurium A1-R and TEM alone, Only trametinib (TRA) could regress the tumor. Vemurafenib (VEM) was not very effective despite the fact that it targets the BRAF-V600E mutation in this tumor. ** p ≤ 0.0001. Error bars = SD [55] .
In a subsequent study with this BRAF-V600E mutant melanoma PDOX, TEM combined with S. typhimurium A1-R was significantly more effective than either S. typhimurium A1-R and TEM alone, causing regression of the tumor (Figure 4 ). Confocal microscopy showed that the S. typhimurium A1-R could directly target the melanoma PDOX and cause tumor necrosis [56] .
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Materials and Methods

Mice
Athymic (nu/nu) nude mice (AntiCancer Inc., San Diego, CA, USA) were used in these studies in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals under Assurance Number A3873-1. Animals were anesthetized with a ketamine mixture via subcutaneous injection of a 0.02 mL solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine and 0.48 mg/kg acepromazine maleate for all surgeries [9, [55] [56] [57] 77 ].
Patient-Derived Tumors
The PDOX models from the University of California Los Angeles (UCLA) were established from a 75-year-old female patient with a melanoma of the right chest wall. The melanoma had a BRAF-V600E mutation. Tumor resection was performed in the Department of Surgery, UCLA. The tumor was provided for PDOX establishment after written informed consent was provided by the patient, and after approval was granted by the Institutional Review Board (IRB) [55] . Another patient melanoma was obtained from a patient at UCSD under IRB approval and informed patient consent [34] .
Establishment of PDOX Models of Melanoma by Surgical Orthotopic Implantation (SOI)
Resected melanoma tissue was immediately transported to AntiCancer Inc. on ice. The BRAF-V600E mutant melanoma tumor fragments (3 mm 3 ) were transplanted to the chest wall of nude mice to mimic the site from which they were resected from the patient [9, [55] [56] [57] 77] . The melanoma from UCSD was directly implanted subdermally and passaged in the back skin of nude mice [34] . All surgeries were performed under ketamine anesthesia.
Preparation and Administration of S. typhimurium A1-R
S. typhimurium A1-R (AntiCancer Inc.), expressing GFP, was cultured in LB medium (Fisher Sci., Hanover Park, IL, USA) and harvested at the late-log phase. The bacteria were washed and diluted with PBS. S. typhimurium A1-R was injected intravenously. A total of 5 × 10 7 colony-forming units (CFU) of S. typhimurium A1-R in 100 µL phosphate-buffered saline (PBS) was administered to each mouse [36] [37] [38] 56 ].
Recombinant Methionase (rMETase) Production
Recombinant L-methionine α-deamino-γ-mercaptomethane lyase (recombinant methioninase (rMETase)) (EC 4.4.1.11) from Pseudomonas putida was previously cloned and produced in Escherichia coli using previously published procedures [74] .
Tumor Histology
The original tumor tissue and PDOX tumor tissue were fixed in 10% formalin. The fixed tumors were embedded in paraffin and then sectioned and stained. Standard bright-light microscopy was used for histopathological analysis [55] .
Confocal Microscopy
The FV1000 confocal microscope (Olympus, Tokyo, Japan) was used for high-resolution imaging of S. typhimurium A1-R. Fluorescence images were obtained using the 20×/0.50 UPLAN FLN and 40×/1.3 Oil Olympus UPLAN FLN objectives [80] .
Treatment Study Design in the PDOX Model of Melanoma
BRAF-V600E mutant melanoma PDOX mouse models were randomized into six groups of 10 mice each: untreated control (n = 10); VEM (30 mg/kg, oral (po) per week (qd) × 14); COB (5 mg/kg, po qd × 14); S. typhimurium A1-R (5 × 10 7 CFU/100 mL, intravenous (i.v.), per week (qw) × 2); COB (30 mg/kg, 5 mg/kg, po qd × 14) combined with VEM (30 mg/kg, po qd × 14); VEM (30 mg/kg, po qd × 14) combined with S. typhimurium A1-R (5 × 10 7 CFU/100 mL, i.v., qw × 2); rMETase (100 units, intraperitoneal (i.p.), 14 consecutive days, n = 10) [9] . For the melanoma tumor from UCSD, the treatment was as follows: 5-fluorouracil (5-FU) (10 mg/kg, i.p., once per week) and CDDP (3 or 5 mg/kg, i.p., once per week) were administered. S. typhimurium A1-R (3 or 5 × 10 7 CFU/body, i.v., once per week) was also injected [34] . Tumor volume (mm 3 ) was calculated from length (mm) × width (mm) × width (mm) × 0.5. Data points represent mean ± SD [9] .
Intratumor L-Methionine Levels
After the completion of rMETase treatment, each tumor was sonicated for 30 s on ice and centrifuged at 12,000 rpm for 10 min. Supernatants were collected and protein levels were measured using the Coomassie Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). L-methionine levels were determined using a high-pressure liquid chromatography (HPLC) procedure we developed previously [81, 82] . Methionine levels were normalized to tumor protein by standard procedures.
Conflicts of Interest:
The author declares no conflict of interest.
